115 related articles for article (PubMed ID: 12637645)
1. Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone.
Upton RA; Knutson JC; Bishop CW; LeVan LW
Nephrol Dial Transplant; 2003 Apr; 18(4):750-8. PubMed ID: 12637645
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Effects of i.v. and oral 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in dogs with chronic renal failure.
Takahashi F; Furuichi T; Yorozu K; Kawata S; Kitamura H; Kubodera N; Slatopolsky E
Nephrol Dial Transplant; 2002; 17 Suppl 10():46-52. PubMed ID: 12386269
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D
Pandey R; Zella JB; Zhu JG; Plum LA; Clagett-Dame M; Blaser WJ; Bedale W; DeLuca HF; Coyne DW
Drugs R D; 2017 Dec; 17(4):597-605. PubMed ID: 28905271
[TBL] [Abstract][Full Text] [Related]
5. The vitamin D prodrugs 1alpha(OH)D2, 1alpha(OH)D3 and BCI-210 suppress PTH secretion by bovine parathyroid cells.
Brown AJ; Ritter CS; Knutson JC; Strugnell SA
Nephrol Dial Transplant; 2006 Mar; 21(3):644-50. PubMed ID: 16221703
[TBL] [Abstract][Full Text] [Related]
6. 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells.
Ritter CS; Armbrecht HJ; Slatopolsky E; Brown AJ
Kidney Int; 2006 Aug; 70(4):654-9. PubMed ID: 16807549
[TBL] [Abstract][Full Text] [Related]
7. Comparative review of the pharmacokinetics of vitamin D analogues.
Bailie GR; Johnson CA
Semin Dial; 2002; 15(5):352-7. PubMed ID: 12358640
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of High vs. Conventional Ergocalciferol Dose for Increasing 25-Hydroxyvitamin D and Suppressing Parathyroid Hormone Levels in Stage III-IV CKD with Vitamin D Deficiency/Insufficiency: A Randomized Controlled Trial.
Thimachai P; Supasyndh O; Chaiprasert A; Satirapoj B
J Med Assoc Thai; 2015 Jul; 98(7):643-8. PubMed ID: 26267985
[TBL] [Abstract][Full Text] [Related]
9. Doxercalciferol treatment of secondary hyperparathyroidism.
Dennis VC; Albertson GL
Ann Pharmacother; 2006 Nov; 40(11):1955-65. PubMed ID: 17062838
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D analogs: perspectives for treatment.
Brown AJ; Slatopolsky E
Miner Electrolyte Metab; 1999; 25(4-6):337-41. PubMed ID: 10681662
[TBL] [Abstract][Full Text] [Related]
11. Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient.
Sprague SM; Ho LT
Clin Nephrol; 2002 Aug; 58(2):155-60. PubMed ID: 12227689
[TBL] [Abstract][Full Text] [Related]
12. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer.
Liu G; Oettel K; Ripple G; Staab MJ; Horvath D; Alberti D; Arzoomanian R; Marnocha R; Bruskewitz R; Mazess R; Bishop C; Bhattacharya A; Bailey H; Wilding G
Clin Cancer Res; 2002 Sep; 8(9):2820-7. PubMed ID: 12231522
[TBL] [Abstract][Full Text] [Related]
14. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
Sharma A; Ketteler M; Marshall TS; Khan SS; Schumock GT
J Med Econ; 2013 Sep; 16(9):1129-36. PubMed ID: 23834479
[TBL] [Abstract][Full Text] [Related]
15. New vitamin D analogs.
Slatopolsky E; Finch J; Brown A
Kidney Int Suppl; 2003 Jun; (85):S83-7. PubMed ID: 12753273
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men.
Brandi L; Egfjord M; Olgaard K
Nephrol Dial Transplant; 2002 May; 17(5):829-42. PubMed ID: 11981071
[TBL] [Abstract][Full Text] [Related]
17. Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients.
Dogan E; Erkoc R; Sayarlioglu H; Soyoral Y; Dulger H
Ren Fail; 2008; 30(4):407-10. PubMed ID: 18569914
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity in serum 25-hydroxy-vitamin D response to cholecalciferol in elderly women with secondary hyperparathyroidism and vitamin D deficiency.
Giusti A; Barone A; Pioli G; Girasole G; Razzano M; Pizzonia M; Pedrazzoni M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2010 Aug; 58(8):1489-95. PubMed ID: 20646099
[TBL] [Abstract][Full Text] [Related]
19. Mortality risk among hemodialysis patients receiving different vitamin D analogs.
Tentori F; Hunt WC; Stidley CA; Rohrscheib MR; Bedrick EJ; Meyer KB; Johnson HK; Zager PG;
Kidney Int; 2006 Nov; 70(10):1858-65. PubMed ID: 17021609
[TBL] [Abstract][Full Text] [Related]
20. [Frontiers in vitamin D; basic research and clinical application. Vitamin D and secondary hyperparathyroidism].
Tanaka H; Komaba H; Fukagawa M
Clin Calcium; 2011 Nov; 21(11):27-34. PubMed ID: 22040818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
